Healthcare industry

The great potential of artificial intelligence (AI) and machine learning for the life sciences – from basic research in biology to medical applications – has largely been neglected to date. A new research unit aims to support AI research in the life sciences and to forge international links with the activities in Heidelberg.

Stem cell therapy for regenerating intervertebral discs - 16/07/2020

Ulm’s simulator has Europe’s back

Back pain is often caused by intervertebral disc disorders. Much has already been tried and is available to help patients. Despite extensive progress, there is still no surefire recipe for success. iPSpine, an EU-funded project to which researchers from Ulm are contributing interdisciplinary engineering and biomedical expertise, aims to design a novel therapy for back pain based on intervertebral disc regeneration.

Translational oncology - 26/05/2020

Translation: driver of cancer medicine

The fight against cancer is a pressing issue. Although technological advances in the treatment, prevention and early detection of cancer have improved over the past few decades, the number of people affected is increasing. Cancer medicine now wants to counteract this by joining forces with other players involved in the field.

Five new companies from the Stuttgart/Tübingen region in southwestern Germany have joined the Cyber Valley Start-Up Network. The innovative technologies and products of AmbiGate, Cytolytics, Mojin Robotics, plus10 and Tactai aim to achieve ground-breaking improvements in the fields of public health, manufacturing, and customer service. These start-ups join ten other companies that are already part of the Cyber Valley Start-Up Network.

The NMI Reutlingen is currently tackling a major problem associated with antibody tests for the detection of COVID-19: false positive test results.

Falsified chloroquine tablets identified in Africa - University of Tübingen supports local pharmacists in the analysis.

Identification of contacts is one of the most important measures to mitigate the spread of the Corona virus. Tracing apps are to help. Technical implementation, however, is associated with the risk of data misuse and the approaches presented so far do not sufficiently protect privacy. Researchers of Karlsruhe Institute of Technology (KIT) and of the FZI Research Center for Information Technology have now proposed an app that enhances privacy.

Medical safety eyewear, disinfectant dispensers and ventilators from 3D printers – experts from the Fraunhofer Institute for Manufacturing Engineering and Automation IPA are using their technological expertise in the fight against the coronavirus pandemic.

Scientists from the Tübingen Competence Center for Machine Learning and physicians from the University Hospital of Tübingen have developed an app that uses anonymous health data to contribute to a better understanding of the novel coronavirus.

Prime Vector Technologies GmbH - 09/04/2020

A modular brick system for developing a COVID-19 vaccine

Prime Vector Technologies GmbH (PVT), a start-up company based in Tübingen in southern Germany, uses a modular brick system to develop vaccines against cancer and infectious diseases. The PVT team is currently working flat out to develop a COVID-19 vaccine.

Scientists from Heidelberg and Mannheim launch research and development task force

Press release - 08/04/2020

“Access checker” remotely measures body temperature in addition to heart and breathing rate

An innovative measurement method is helping to detect people infected with coronavirus from a safe distance. It detects fever, increased pulse rates and fast breathing without endangering the person conducting the testing. Fraunhofer IPA and Fraunhofer IAO are currently testing the procedure at the Robert Bosch Hospital in Stuttgart.

Today, the European Commission launched an advisory panel on COVID-19 composed of epidemiologists and virologists from different Member States to formulate EU guidelines on science-based and coordinated risk management measures.

CureVac AG, a clinical stage biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that company founder and Chairman of the Supervisory Board Ingmar Hoerr is replacing Daniel Menichella in his function as Chief Executive Officer (CEO).

Article - 08/11/2019

Nanorobots as future minimally invasive tools for the eye

It is difficult to place drugs in the right place in the eye. When using droplets, only a small fraction of the drug reaches its target. Injecting drugs into the eye is also more a matter of luck than judgement. Basic researchers at the Max Planck Institute for Intelligent Systems Stuttgart have developed a nanorobot that can be loaded with active ingredients for treating eye diseases and directed through the solid tissue of the vitreous body.

Article - 09/10/2019

Epigenomics from the Cyber Valley

Cyber Valley Stuttgart-Tübingen is a European hotspot for artificial intelligence and home to many renowned experts and scientists. They are now joined by Gabriele Schweikert, who heads up the Computational Epigenomics research group in the Cyber Valley’s Division of Computational Biology. Schweikert is interested in exploring epigenetic mechanisms using machine learning methods.

Spindiag, a young medtech company in the German state of Baden-Württemberg, announced today the expanded financing of its first Series A. Based on a proprietary microfluidic technology first researched at the company’s mother institute Hahn-Schickard, Spindiag is developing a sustainable platform to diagnose infections and, as a first product, a rapid test for multidrug-resistant bacteria.

Article - 23/04/2019

How can care infrastructures benefit from digitization?

The pilot project NeCTra (Networking - Care - Transparency) investigates how care processes within an urban social environment can be improved by using digital technologies. The goal is to bring together all partners and institutions in real time so that people in need of care and those seeking advice receive appropriate support more quickly.

Expert interview on NTDs – part 1 - 11/04/2019

Neglected tropical diseases – Carsten Köhler: impulses from Baden-Württemberg

More than one billion people worldwide suffer from neglected tropical diseases (NTDs). NTDs are mostly poverty-related infectious diseases that prevail in tropical countries due to lack of research and measures to detect, prevent and control them. Dr. Dr. Carsten Köhler reports on the political, economic and scientific contributions Germany and Baden-Württemberg can make to successfully change this situation.

The High-Tech Gründerfonds (HTGF) and two private investors are convinced of the importance of single-cell isolation for the production of biopharmaceuticals and for genetic analysis in research and diagnostics. EUR 3 million will be invested in the further development of the technology, the expansion of the sales organization and in opening up further applications for Cytena’s single-cell printers.

Article - 05/03/2019

Vaccination against oncogenic Epstein-Barr viruses

Almost all humans are infected with Epstein-Barr viruses (EBV), which are linked to the development of benign diseases such as infectious mononucleosis as well as several cancers. Scientists from the German Cancer Research Center have developed a new strategy for creating a vaccine that targets different EBV virus life phases and has the potential to provide effective protection against EBV infection.

Article - 24/01/2019

Scientists to combat antibiotic-resistant bacteria in wastewater

In Germany, around 1,500 tonnes of antibiotics per year are administered to humans and animals. As a result, more and more bacteria are developing resistance to common antibiotics. As part of HyReKA, a cooperative project funded by the BMBF, scientists led by Professor Thomas Schwartz from the KIT are investigating how antibiotic-resistant pathogens spread and how they can be prevented from doing so.

Expert interview - 16/01/2019

Cybersecurity is an important issue for the pharmaceutical industry

In an increasingly interconnected world, the pharmaceutical and biotechnology sectors need to be aware of cybersecurity threats in manufacturing. We talked about these threats with Holger Mettler who is in charge of computer system validation and cybersecurity at Exyte (formerly M + W), a global enterprise that designs, engineers and constructs complex manufacturing facilities and buildings for the life sciences industry.

Anniversary - 12/12/2018

15 years of BIOPRO: Pooling competencies – pushing innovations

This is the leitmotif of BIOPRO Baden-Württemberg GmbH, which was founded in 2003. 15 years is a good time to pause for a moment and take a look at BIOPRO’s work and achievements. As a central point of contact and wholly-owned subsidiary of the Baden-Württemberg government whose main objective is to promote networking, BIOPRO knows only too well that progress is not made alone, but in collaboration with others.